Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $3 from $7 and keeps a Buy rating on the shares after meeting with its management team regarding its Q2 performance and its commercial outlook. The company’s upcoming FDA Type C meeting presents an intriguing scenario to buy the stock at the current price given the opportunity to bypass a second Phase 3 study, the analyst tells investors in a research note. Roth adds however that its price target cut reflects equity dilution and its discount cash-flow model updates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals price target lowered to $3 from $7 at Roth Capital
- Reviva Pharmaceuticals price target lowered to $2 from $5 at Maxim
- Reviva Pharmaceuticals reports Q2 EPS (12c) vs. (26c) last year
- Reviva Pharmaceuticals Announces Public Offering Agreement
- Reviva Pharmaceuticals prices 20M shares at 50c in public offering